Neuroblastoma: Recent Developments in Assessment and Management
Not all children with neuroblastoma succumb to the disease. “Good-prognosis”, “intermediate-prognosis” and “bad-prognosis” patients can now be defined; unfortunately, the latter predominate and give the tumour its overall unsavoury reputation. Children with good-prognosis disease are often cured by surgery alone; by contrast there is little evidence to date of a fall in mortality for bad-prognosis patients. However, neuroblastoma is a chemoresponsive and radioresponsive tumour, and the “tail” on the survival curves published for several series of children treated with combination drug therapy indicate that, even for patients with advanced disease, cure is a less than remote possibility.
KeywordsShrinkage Oncol Melphalan Cyclophosphamide Catecholamine
Unable to display preview. Download preview PDF.
- 5.Goldman AJ, Vivian GC, Gordon I, Pritchard J, Kemshead JT Immunolocalisation of neuroblastoma using radiolabelled monoclonal antibodies. Proc Amer Soc Clin Oncol (Abstr C-271) 19: 70Google Scholar
- 8.Kemshead JT, Rembaum A, Ugelstad J (1982a) The potential use of monoclonal antibodies and microspheres containing magnetic compounds to remove neuroblastoma cells from bone marrow to be used in autologous transplantation programmes. Proc Am Soc Cancer Res Proc Am Soc Clin Oncol (Abstr C143 ) 23: 36Google Scholar
- 12.Malpas JS, Kemshead JT, Pritchard J, Greaves MF (1982) Heterogeneity in cell surface antigens on human neuroblastoma cells. In: Proceedings of the XIIIth meeting of the International Society of Paediatric Oncology. Excerpta Medica, Amsterdam pp 90–94Google Scholar
- 16.Pritchard J, Shafford EA, Craft AE, McElwain TJ (1981) High doses melphalan (HDM) with autologous bone marrow (ABM) for advanced neuroblastoma. Proc Am Soc Clin Oncol (Abstr C 307 ) 22: 410Google Scholar